1. Home
  2. UAMY vs CAPR Comparison

UAMY vs CAPR Comparison

Compare UAMY & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UAMY
  • CAPR
  • Stock Information
  • Founded
  • UAMY 1968
  • CAPR 2005
  • Country
  • UAMY United States
  • CAPR United States
  • Employees
  • UAMY N/A
  • CAPR N/A
  • Industry
  • UAMY Metal Fabrications
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • UAMY Industrials
  • CAPR Health Care
  • Exchange
  • UAMY Nasdaq
  • CAPR Nasdaq
  • Market Cap
  • UAMY 316.8M
  • CAPR 324.6M
  • IPO Year
  • UAMY N/A
  • CAPR N/A
  • Fundamental
  • Price
  • UAMY $4.54
  • CAPR $6.28
  • Analyst Decision
  • UAMY Strong Buy
  • CAPR Strong Buy
  • Analyst Count
  • UAMY 5
  • CAPR 8
  • Target Price
  • UAMY $3.60
  • CAPR $24.75
  • AVG Volume (30 Days)
  • UAMY 6.3M
  • CAPR 1.4M
  • Earning Date
  • UAMY 08-12-2025
  • CAPR 08-11-2025
  • Dividend Yield
  • UAMY N/A
  • CAPR N/A
  • EPS Growth
  • UAMY N/A
  • CAPR N/A
  • EPS
  • UAMY N/A
  • CAPR N/A
  • Revenue
  • UAMY $25,728,046.00
  • CAPR $13,392,150.00
  • Revenue This Year
  • UAMY $209.07
  • CAPR N/A
  • Revenue Next Year
  • UAMY $98.95
  • CAPR $6,061.53
  • P/E Ratio
  • UAMY N/A
  • CAPR N/A
  • Revenue Growth
  • UAMY 134.91
  • CAPR N/A
  • 52 Week Low
  • UAMY $0.49
  • CAPR $3.98
  • 52 Week High
  • UAMY $5.13
  • CAPR $23.40
  • Technical
  • Relative Strength Index (RSI)
  • UAMY 64.05
  • CAPR 36.33
  • Support Level
  • UAMY $4.38
  • CAPR $6.17
  • Resistance Level
  • UAMY $5.13
  • CAPR $7.30
  • Average True Range (ATR)
  • UAMY 0.40
  • CAPR 0.43
  • MACD
  • UAMY 0.01
  • CAPR -0.11
  • Stochastic Oscillator
  • UAMY 69.56
  • CAPR 4.53

About UAMY United States Antimony Corporation

United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: